Evidence map›Paper›PMID 28894797›Full record

ArticleLaryngoscope investigative otolaryngology2016

Tumoral Expression of CD44 and HIF1α Predict Stage I Oral Cavity Squamous Cell Carcinoma Outcome.

Johannes Dunkel, Samuli Vaittinen, Petri Koivunen, Jussi Laranne, Markus J Mäkinen, Satu Tommola, Heikki Irjala

Open access · goldAbstract read
In one paragraph

Article in Laryngoscope investigative otolaryngology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Johannes DunkelMedicity Research Laboratory and Turku Doctoral Programme of Molecular Medicine University of Turku.
Samuli Vaittinenthe Department of Pathology University of Turku and Turku University Hospital Turku.
Petri Koivunenthe Research Center for Otorhinolaryngology and Ophthalmology, University of Oulu and Department of Otorhinolaryngology and Medical Research Center Oulu, Oulu University Hospital.
Jussi Larannethe Department of Otorhinolaryngology Head and Neck Surgery Tampere University Hospital.
Markus J Mäkinenthe Department of Pathologyand Medical Research Center Oulu, Oulu University Hospital and University of Oulu Oulu.
Satu Tommolathe Department of Pathology University of Tampere and Tampere University Hospital Tampere Finland.
Heikki Irjalathe Department of Otorhinolaryngology Head and Neck Surgery Turku University Hospital.
Oulu University Hospital · FITampere University Hospital · FIUniversity of Turku · FITurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectives/hypothesisNo biomarkers are used to estimate the prognosis in oral cavity squamous cell carcinoma (OSCC). In our previously published work, we have reported the prognostic value of CD44 and hypoxia inducible factor (HIF)-1α in patients with stage I disease. STUDY

designIn this study, we tested our previous observations in a larger cohort. We also studied the predictive value of common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 in this material.

methodsCD44, HIF1α, and CLEVER-1 were immunohistochemically analyzed in paraffin-embedded tissue material of stage I OSCC patients treated at three Finnish university hospitals. Microscopy results were correlated with OSCC outcome.

resultsAs in our pilot study, the CD44

conclusionOur results suggest that immunohistochemistry of CD44 and HIF1α may be useful in identification of patients with poor prognoses. These parameters could be used to select the optimal treatment modalities for stage I OSCC patients. LEVEL OF EVIDENCE: 2b.

Indexed as

BiomarkersCD44CLEVER‐1HIF1αOSCC

Identifiers

PMID28894797
PMCPMC5580857
OpenAlexW2299116924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.